Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyeocco Serum Antibodies Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrenteoccoPolicy N/A

    Serum Antibodies for Diagnosis of Inflammatory Bowel Disease

    Customize your policy alerts

    Sign up for all eocco policy alerts

    Know when eocco releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage, and exclusions for serum antibody panels (eg, ASCA, ANCA and others), TPMT genetic/phenotypic testing, thiopurine metabolite monitoring, fecal lactoferrin, and measurement of therapeutic drug levels for diagnosis or management of inflammatory bowel disease for EOCCO members.

    Policy Summary
    Payereocco
    PolicySerum Antibodies for Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2026
    Next Review DateJun 24, 2026
    Key ActionSubmit specialist chart notes, diagnostic study results (eg, colonoscopy), and pathology report with prior authorization requests to support medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10%Indeterminate IBD

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    50-80%
    ANCA in UC
    46-70%ASCA in CD
    One lifetimeTPMT testing
    MultipleExperimental tests

    Coverage and Medical Necessity Criteria

    Baseline TPMT genotype testing (covered)

    Covered when ANY of the following baseline indications are met (one time during patient's lifetime):

    Baseline TPMT testing indications: a. To determine candidacy for thiopurine treatment prior to initiation of 6-mercaptopurine (6-MP), azathioprine (AZA), or thioguanine (6-TG); b. In patients on thiopurine therapy with abnormal CBC results that do not respond to dose reduction.

    Covered one time during the patient's lifetime.

    Monitoring thiopurine metabolites (covered)

    Considered medically necessary for EITHER of the following monitoring indications:

    Thiopurine metabolite monitoring: a. To measure blood levels in individuals suspected of having toxic responses to azathioprine and/or 6-mercaptopurine (e.g., hepatotoxicity or myelotoxicity); b. To measure drug levels in individuals who have not responded to therapy.

    Includes measurement of 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMRP)/6-MMPN as listed.

    Tests considered experimental, investigational, or unproven (not covered)

    The following tests are considered experimental/investigational for diagnosis, differentiation, or management of IBD:

    Serologic antibody panels and other listed tests: ASCA, ANCA, ACCA, ALCA, AMCA, Anti-C, Anti-L, OmpC, anti-Cbir1, 12 antibodies, Prometheus IBD sgi diagnostic test, ASMA (for IBD), measurement of antibodies and/or serum levels to biologic agents (eg, infliximab, adalimumab, vedolizumab, ustekinumab), Anser IFX/ADA/VDZ/UST and similar tests.

    Effectiveness for these indications has not been established; considered experimental/investigational and not covered for diagnosis, distinction of UC vs Crohn's, management of IBD, or other non-established indications.

    Fecal lactoferrin

    Coverage stance depends on indication:

    Fecal lactoferrin for IBD vs IBS: Fecal lactoferrin is considered medically necessary for distinguishing inflammatory bowel disease (Crohn's disease, ulcerative colitis) from irritable bowel syndrome.

    Fecal lactoferrin is considered experimental/investigational for evaluation of infectious diarrhea, Clostridium difficile infection, and all other indications.

    Tests listed in this policy as experimental, investigational, or unproven are excluded from coverage for diagnosis of inflammatory bowel disease (IBD), for distinguishing ulcerative colitis from Crohn’s disease, for management of IBD, and for all other indications where effectiveness has not been established. Examples include serologic antibody panels and related assays such as ASCA, ANCA, ACCA, ALCA, AMCA, Anti‑C, Anti‑L, OmpC, anti‑Cbir1, 12 antibodies, Prometheus IBD sgi, and ASMA (when used for IBD), as well as tests that measure antibodies or serum drug levels for biologic agents and similar panels.

    Use of serologic antibody panels (for example, ASCA, ANCA, and other listed antibodies) and measurement of antibodies or serum drug levels to biologic agents (for example, assays for infliximab, adalimumab, vedolizumab, ustekinumab and branded panels such as Anser IFX/ADA/VDZ/UST) is considered experimental and investigational for diagnosing IBD, distinguishing ulcerative colitis from Crohn’s disease, or otherwise managing IBD because their effectiveness for these indications has not been established.

    Billing and Coding

    Covered CPT Codes (when criteria met)CPTCovered
    82630TPMT (thiopurine S-methyltransferase) gene analysis / enzyme activity (as listed in policy text)
    82657Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen (listed for TPMT)
    83630Lactoferrin, fecal; qualitative
    83631Lactoferrin, fecal; quantitative
    CPT/HCPC Codes NOT CoveredCPTNot Covered
    86256Fluorescent noninfectious agent antibody; titer, each antibody
    82397ACCA, ALCA, AMCA, Anti-C, Anti-L, ANCA, ASCA, OmpC, anti-Cbir-1, 12 antibodies, and ASMA (listed under not covered)
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen (listed under not covered)
    83518Immunoassay; qualitative or semi-quantitative; multiple step method (listed under not covered)
    83519Immunoassay; qualitative or semiquantitative, single step method (listed under not covered)
    83520Quantitative, by radioimmunoassay (eg, RIA) (listed under not covered)
    86021Immunoassay, analyte, quantitative; not otherwise specified (listed under not covered)
    86255Antibody identification; leukocyte antibodies / Fluorescent noninfectious agent antibody; screen, each antibody (listed under not covered)
    86671Antibody; fungus, not elsewhere specified (listed under not covered)
    88350Immunofluorescence, per specimen; each additional single antibody stain procedure (listed under not covered)
    1–10 of 13
    1/2

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior authorization submission requirements

    Prior authorization requests must include supporting clinical documentation to demonstrate medical necessity. Submit specialist chart notes, the ordering specialist's history and physical, results of colonoscopy and any other diagnostic studies performed, and the pathology report with the prior authorization request.

    • Chart notes and history and physical from ordering specialist
    • Results of colonoscopy and other diagnostic studies performed
    • Pathology report
    Note

    Prior authorization submission — completeness reminder

    Include the full list of required supporting documents with the prior authorization; incomplete submission may delay review. Ensure chart notes, H&P, diagnostic study results, and pathology are attached as described in the policy.

    • Attach ordering specialist chart notes and history & physical

    Clinical Background

    Inflammatory bowel disease (IBD) encompasses Crohn’s disease and ulcerative colitis; diagnosis relies primarily on radiographic, endoscopic, and histologic evaluation rather than serologic testing. Serologic markers such as ANCA and ASCA have been studied to help differentiate UC from CD but lack sufficient sensitivity and specificity to definitively establish the diagnosis. Approximately 10% of patients have indeterminate colitis, and serologic tests are not considered reliable enough to replace standard diagnostic approaches.

    Test Definitions and Performance Characteristics

    ANCA — Anti‑neutrophilic cytoplasmic antibody
    DefinitionAnti‑neutrophilic cytoplasmic antibody (ANCA).
    Reported detection in ulcerative colitis50–80% of UC patients (reported range).
    Reported detection in Crohn's disease10–40% of CD patients (reported range).
    ASCA — Anti‑Saccharomyces cerevisiae antibody
    DefinitionAnti‑Saccharomyces cerevisiae antibody (ASCA).
    Reported detection in Crohn's disease46–70% of CD patients (reported range).
    Reported detection in ulcerative colitis
    Policy Summary
    Payereocco
    PolicySerum Antibodies for Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJun 24, 2026
    Next Review DateJun 24, 2026
    Key ActionSubmit specialist chart notes, diagnostic study results (eg, colonoscopy), and pathology report with prior authorization requests to support medical necessity.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and CodingPrior Authorization and Documentation RequirementsClinical BackgroundTest Definitions and Performance Characteristics
  1. Attach results of colonoscopy and other diagnostic studies
  2. Attach pathology report
  3. Documentation Required

    Required supporting documentation

    Prior authorization requests should include the ordering specialist's chart notes and history and physical, results of colonoscopy and other diagnostic studies, and the pathology report to support the request.

    • Chart notes and history and physical from ordering specialist
    • Results of colonoscopy and other diagnostic studies performed
    • Pathology report
    Denial Risk

    Experimental/investigational tests — denial risk

    Requests for ASCA, ANCA, ACCA, ALCA, AMCA, Anti-C, Anti-L, OmpC, anti‑Cbir1, Prometheus IBD sgi, ASMA (for IBD), and similar serologic antibody panels or measurement of antibodies/serum levels to biologics are considered experimental/investigational and may be denied.

    • ASCA (anti‑Saccharomyces cerevisiae antibodies)
    • ANCA (anti‑neutrophil cytoplasmic antibodies)
    • ACCA, ALCA, AMCA
    • Anti‑C, Anti‑L, OmpC, anti‑Cbir1
    • Prometheus IBD sgi diagnostic test
    • ASMA for IBD; measurement of antibodies/serum levels to biologics
    6–12% of UC patients (reported range).
    TPMT testing — genotype or enzyme activity
    DefinitionTesting of thiopurine methyltransferase (TPMT) by genotype or enzyme activity to guide thiopurine therapy (azathioprine, 6‑mercaptopurine, thioguanine).
    Regulatory recommendationFDA recommends determination of TPMT (either enzyme or genotype) prior to initiating azathioprine or 6‑mercaptopurine.
    Covered indicationBaseline TPMT genotype testing is considered medically necessary one time during the patient's lifetime to determine candidacy for thiopurine treatment or for abnormal CBC on therapy that does not respond to dose reduction.